TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00602056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Redesigned immunization card
Description: A low cost nad simplified redesigned immunization card

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Center based education to mothers/caregivers
Description: A 2-3 minute center based education to mothers/caregivers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Redesigned immunization card with center based education to mother/caregivers
Description: Redesigned immunization card with center based education to mother/caregivers
Study: NCT00454948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based nutrition sessions and play group exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based nutrition sessions and mail-out activities
Study: NCT02362529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 50 mg and 100 mg capsule, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose monohydrate in identical gel capsules to minocycline, oral administration.

Intervention type: DRUG
Group type: OTHER
Intervention: Celecoxib
Description: 100 mg and 200 mg capsules, oral administration.
Study: NCT03602170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 20 minutes of exercise by completing 10 repetitions of 60 seconds of exercise at 90-95% maximal heart rate with 60 seconds of active rest between each repetition at 50-60% maximal heart rate.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Continuous Training
Description: Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 30 minutes of continuous exercise at 65-70% maximal heart rate.
Study: NCT01375348

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ultiva (remifentanil) or placebo
Description: 0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultiva (remifentanil) or placebo
Description: 0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
Study: NCT03912844

Intervention type: PROCEDURE
Intervention: SIRT followed by liver resection or liver transplantation
Description: The ESSURE registry is a prospective observational study. Patients are only asked to be enrolled when they are treated with SIR-Spheres microspheres followed by liver resection/liver transplantation or when SIRT has been performed with the intention to downsize/ downstage the tumor, to induce hypertrophy of the contralateral lobe, making the patient eligible for a future liver resection/transplantation. In no way will participation in the registry influence the way in which the patient is treated according to the treating clinician, or will it influence the quality of the treatment. If a patient is included in the registry, a documented decision of a multidisciplinary tumour board for the treatment algorithm including SIRT must be available. The follow-up periods depend on the treating clinician and local practice and guidelines. Typically, the follow ups are done every three months. So data of a single patient will be included over two years after the treatment.
Study: NCT01918410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact Lens with alginic acid
Description: Worn for 7 days, at least 8 hours a day

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Contact Lens without alginic acid
Description: Worn for 7 days, at least 8 hours a day
Study: NCT02242864

Intervention type: DRUG
Intervention: Micardis®

Intervention type: DRUG
Intervention: MicardisPlus®
Study: NCT00530855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
Study: NCT03657433

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate 325mg
Description: Oral tablets supplied for home use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Ferumoxytol will be administered in two infusions, one week apart
Study: NCT01292876

Intervention type: DEVICE
Group type: OTHER
Intervention: Extracellular Matrix
Description: Extracellular Matrix
Study: NCT02115594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Study: NCT04436328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Surgical treatment of native vertebral osteomyelitis consisting of debridement, spinal decompression and instrumentation using hardware. Additional standard antimicrobial therapy, according to the pathogen and its antimicrobial susceptibility (intravenous route during first 2 weeks, followed by oral route for additional 4 weeks).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial treatment
Description: No surgical intervention, antimicrobial therapy only, bed rest or temporary external immobilization of affected spinal segment with orthopedic orthesis. Antimicrobial therapy will be administrated according to the pathogen type and antimicrobial susceptibility, with initial intravenous administration for 2 weeks, followed by oral antibiotics for 4 weeks to complete 6 weeks of total therapy.
Study: NCT00717756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 25 mg po qd x 21 days then 1 week off equals one cycle
Study: NCT00770991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Black raspberry (BRB) Slurry
Description: 20 grams BRB Slurry

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Black Raspberry (BRB) Suppositories
Description: Two, 730 mg BRB suppositories QHS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Black Raspberry (BRB) Suppositories
Description: Two, 730 mg BRB suppositories QHS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Black Raspberry (BRB) Placebo Slurry
Description: 20 grams BRB placebo slurry
Study: NCT03336983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid

Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide
Description: Patients from both arms will be treated with LHRH-A + Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients from both arms will be treated with LHRH-A + Enzalutamide
Study: NCT02668783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring
Description: Up to 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal ring
Description: Up to 4 cycles (or 6 cycles if also participating in the extension) of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.
Study: NCT00840983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed cord clamping
Description: cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
Study: NCT02041494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventralight

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice
Study: NCT01303991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hexvix PDT with Karl Storz T-Light
Study: NCT02165579

Intervention type: OTHER
Intervention: 1 cohort, standard care, observational
Description: This is one cohort standard care observational study. 40 diabetic patients admitted to Parkland hospital with a foot infection. We will enroll a representative cross section of subjects with diabetic foot infection. Patient will be consented and will receive therapy based on standard protocols. Currently patients with suspected osteomyelitis have bone biopsies to identify bacterial pathogens and verify MRI diagnosis. Repeat bone biopsies are performed at the end of therapy to verify that osteomyelitis has been successfully treated. Serum to measure procalcitonin will be obtained at baseline, week 3 and week 6. Tissue samples will be obtained at Baseline, Week 3 and Week 6 for tissue culture.
Study: NCT00720850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
Study: NCT02115594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT01081093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: additional temporary pacewire
Description: Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
Study: NCT00108602

Intervention type: DRUG
Group type: OTHER
Intervention: acetazolamide
Study: NCT00831779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 5 mg, once daily, 12 weeks
Study: NCT00570687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: Inhalation 15U/30U
Study: NCT02728505

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SinuSurf irrigation twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SinuSurf irrigation twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NeilMed Sinus rinse irrigation twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeilMed Sinus rinse irrigation twice daily
Study: NCT00579579

Intervention type: BEHAVIORAL
Intervention: Questionaires
Description: Prior to surgery, patients will be asked to complete baseline surveys. In addition, a random subsample of approximately 30 patients will be asked to participate in a short qualitative interview to explore expectations regarding bowel function and quality of life following surgery. Follow-up surveys will be completed at 6, 12 and 24 months after bowel continuity has been restored (defined by their last surgical procedure). Patients with a permanent stoma will receive the Stoma-specific QOL questions in place of the MSKCC Bowel Function Instrument at 6 and 12 months after initial surgery.
Study: NCT01835795

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Swiss DolorClast® CLASSIC applicator
Description: Radial Extracorporeal Shock Wave applicator use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Swiss DolorClast® CLASSIC placebo applicator
Description: Placebo applicator, use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
Study: NCT00707525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preimplantation Genetic Diagnosis
Description: Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.
Study: NCT01448772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol Capsules, 5 mg
Description: Comparison of different routes of administration of a drug using the approved Abbott 5 mg capsule product under fasting conditions; two treatment periods with a washout period separating the study periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol Oral Solution
Description: Comparison of different routes of administration of a drug using a proposed oral solution formulation under fasting conditions; two treatment periods with a washout period separating the study periods
Study: NCT04952025

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic criteria
Description: Diagnostic criteria of ALS
Study: NCT00347009

Intervention type: DRUG
Group type: OTHER
Intervention: adefovir dipivoxil
Description: 10mg once daily
Study: NCT01764620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic taping applied with tension

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Elastic taping applied without tension

Intervention type: OTHER
Group type: OTHER
Intervention: Fatigue protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue protocol

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fatigue protocol
Study: NCT02840656

Intervention type: OTHER
Intervention: oropharyngeal swabbing
Description: microbiological sampling will be performed on buccal mucosa with standard swab. only one sample will be done

Intervention type: OTHER
Intervention: rectal swabbing
Description: same process as oropharyngeal swabbing will be used to collect rectal microbiological sample
Study: NCT06022133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction
Description: Selfemployed dietary sodium restriction
Study: NCT02249728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV PBT2 microtracer and oral PBT2 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral 14C-PBT2
Study: NCT00729612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT00466388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevimeline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cevimeline
Study: NCT00947063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine HCl 50 mg Tablets (Sandoz, Inc)
Study: NCT04017507

Intervention type: DEVICE
Intervention: Oscillating-rotating electric toothbrush
Description: Oscillating-rotating electric toothbrush used twice daily

Intervention type: DEVICE
Intervention: Side-to-side electric toothbrush
Description: Side-to-side electric toothbrush used twice daily

Intervention type: DEVICE
Intervention: Manual toothbrush
Description: Manual toothbrush used twice daily
Study: NCT00151242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 100mg/m² kont. i.v. day 1-7 (induction therapy) 3g/m² 2x/die i.v. day 1,3,5 or day 1,2,3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100mg/m² kont. i.v. day 1-7 (induction therapy) 3g/m² 2x/die i.v. day 1,3,5 or day 1,2,3
Study: NCT00947063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)
Study: NCT00634179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.6 mg/m² given on days 1 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m²
Study: NCT00151242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: 12mg/m² i.v. day 1,3,5 (first induction cycle) 12mg/m² i.v. Tag 1,3 (second induction cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 12mg/m² i.v. day 1,3,5 (first induction cycle) 12mg/m² i.v. Tag 1,3 (second induction cycle)
Study: NCT00634179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg/day given orally on days 1-5
Study: NCT00230971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tigecycline
Description: every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
Study: NCT00151242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 100mg/m² i.v. day 1-3 (induction therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m² i.v. day 1-3 (induction therapy)
Study: NCT00831779

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks
Study: NCT04118348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Practice Alert
Description: An Epic screen pops up for a provider during an eligible 9-11 year-old patient's visit. A prompt requires that the provider respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test.
Study: NCT00230971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone plus metronidazole
Description: Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
Study: NCT02724163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: Antibody-conjugated chemotherapy agent.
Study: NCT03562403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: stimulation of different basal ganglionic nuclei by a inserting a device
Study: NCT00778557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
Study: NCT02724163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin
Description: Anthracycline~(Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: DNA-reactive agent
Study: NCT04118348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Practice Alert
Description: An Epic screen pops up for a provider during an eligible 9-11 year-old patient's visit. A prompt requires that the provider respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Maintenance Topic
Description: An Epic health maintenance topic appears for a provider during an eligible 9-11 year-old patient's visit. The HMT will be highlighted for enhanced visibility, until or unless action is taken.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Maintenance Topic
Description: An Epic health maintenance topic appears for a provider during an eligible 9-11 year-old patient's visit. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
Study: NCT03270449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Description: 10 week multidisciplinary education and exercise
Study: NCT00745810

Intervention type: OTHER
Intervention: Cardiopulmonary bypass
Description: sequential changes of oxidative injuries before and after cardiopulmonary bypass
Study: NCT00712868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic acid
Description: Once a day
Study: NCT02436265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: IV dexamethasone

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine only
Study: NCT00515502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
Study: NCT02724163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.